Target intelligence / Profile preview

Sosondowah ankyrin repeat domain family member C (SOWAHC)

Target
SOWAHC
Molecular classification
Ankyrin repeat domain-containing protein, Other (does not fit traditional categories like receptor, enzyme, transporter, etc.)
01

Overview

Sosondowah ankyrin repeat domain family member C (SOWAHC) is a human protein containing ankyrin repeat domains, a structural motif that facilitates protein–protein interactions and is present in proteins regulating transcription, cell cycle, and cytoskeletal organization. SOWAHC has been identified as a methylation-driven gene in lung squamous cell carcinoma, with hypomethylation and high expression correlating with poor prognosis, suggesting its involvement in regulating transcriptional networks and gene expression relevant to cancer progression. The protein belongs to the ankyrin repeat family but is not classified as a canonical receptor, enzyme, or transporter; its primary function appears to be nuclear regulation rather than cell surface signaling. Predicted protein interactors suggest possible involvement in cytoskeletal processes, but direct functional characterizations are limited. No drugs directly target SOWAHC, and there is no reported involvement in adverse effects or contraindications.

Other names
ANKRD57C2orf26FLJ21870Ankyrin repeat domain-containing protein 57Protein sosondowah homolog C
02

Mechanism of action

Not applicable. No clinically approved drugs or mechanisms of drug action have been described for SOWAHC.

03

Biological functions

Regulation of gene expressionTranscriptional networksProtein–protein interactionsPossibly involved in cell cycle and cytoskeletal organization (based on predicted partners and ankyrin repeat family roles)
04

Disease associations

Cancer (specifically implicated as a prognostic biomarker and possible driver in lung squamous cell carcinoma based on epigenetic and expression data)Other (the ankyrin repeat protein family is also involved in inflammatory and developmental processes, but explicit disease roles for SOWAHC outside cancer are not confirmed)
05

Safety considerations

Unknown. No known therapeutic challenges or safety concerns have been reported due to the lack of drug interactions or clinical development.
06

Biomarkers

Aberrant methylation and elevated expression of SOWAHC serve as prognostic biomarkers in lung squamous cell carcinoma

Beyond the preview

Go deeper on Sosondowah ankyrin repeat domain family member C (SOWAHC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sosondowah ankyrin repeat domain family member C (SOWAHC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call